Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells

Biochemical and Biophysical Research Communications

Volumn 407, Issue 3, 2011, Pages 450-455

  Reed, Suzanne ^a   Li, Huameng ^b   Li, Chenglong ^b   Lin, Jiayuh ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Celecoxib; Rhabdomyosarcoma; STAT3

Indexed keywords

CELECOXIB; CYCLIN D1; INTERLEUKIN 6; PROTEIN BCL 2; STAT3 PROTEIN; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SARCOMA CELL;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COMPUTER SIMULATION; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INTERLEUKIN-6; PHOSPHORYLATION; PYRAZOLES; RHABDOMYOSARCOMA; STAT3 TRANSCRIPTION FACTOR; STEM CELLS; SULFONAMIDES;

EID: 79954464419     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.014     Document Type: Article

References (37)

1. Sultan I., Qaddoumi I., Yaser S., Rodriguez-Galindo C., Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol. 2009, 27:3391-3397.
2. Crist W., Gehan E.A., Ragab A.H., Dickman P.S., Donaldson S.S., Fryer C., Hammond D., Hays D.M., Herrmann J., Heyn R., et al. The third intergroup rhabdomyosarcoma study. J. Clin. Oncol. 1995, 13:610-630.
3. Maurer H.M., Beltangady M., Gehan E.A., Crist W., Hammond D., Hays D.M., Heyn R., Lawrence W., Newton W., Ortega J., et al. The intergroup rhabdomyosarcoma study-I. A final report. Cancer 1988, 61:209-220.
4. Maurer H.M., Gehan E.A., Beltangady M., Crist W., Dickman P.S., Donaldson S.S., Fryer C., Hammond D., Hays D.M., Herrmann J., et al. The intergroup rhabdomyosarcoma study-II. Cancer 1993, 71:1904-1922.
5. Sultan I., Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev. Anticancer Ther. 2010, 10:1285-1301.
6. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. NY Acad. Sci. 2009, 1171:59-76.
7. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
8. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., Baumann H., Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99:252-257.
9. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945-954.
10. Kortylewski M., Jove R., Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005, 24:315-327.
11. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., Chang A., Kraker A., Jove R., Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21:7001-7010.
12. Chen C.L., Loy A., Cen L., Chan C., Hsieh F.C., Cheng G., Wu B., Qualman S.J., Kunisada K., Yamauchi-Takihara K., Lin J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111.
13. Chen C., Loy A., Cen L., Chan C., Hsieh F., Cheng G., Wu B., Qualman S., Kunisada K., Yamauchi-Takihara K., Lin J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111.
14. Ghosh N., Chaki R., Mandal V., Mandal S.C. COX-2 as a target for cancer chemotherapy. Pharmacol. Rep. 2010, 62:233-244.
15. Bruggers C.S., Welsh C.T., Boyer R.S., Byrne J.L., Pysher T.J. Successful therapy in a child with a congenital peripheral medulloepithelioma and disruption of hindquarter development. J. Pediatr. Hematol. Oncol. 1999, 21:161-164.
16. Tian X., Li J., Ma Z.M., Zhao C., Wan D.F., Wen Y.M. Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. J. Exp. Clin. Cancer Res. 2009, 28:58.
17. Paydas S., Tanriverdi K., Yavuz S., Disel U., Sahin B., Burgut R. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann. Oncol. 2003, 14:1045-1050.
18. Shimonovitz S., Hurwitz A., Dushnik M., Anteby E., Geva-Eldar T., Yagel S. Developmental regulation of the expression of 72 and 92kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am. J. Obstet. Gynecol. 1994, 171:832-838.
19. Huey R., Morris G.M., Olson A.J., Goodsell D.S. An empirical free energy force field with charge-based desolvation and intramolecular evaluation. J. Comp. Chem. 2007, 28:1145-1152.
20. Li H., Li C. Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein. J. Comput. Chem. 2010, 31:2014-2022.
21. Frank D.A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007, 251:199-210.
22. Yu L., Chen M., Li Z., Wen J., Fu J., Guo D., Jiang Y., Wu S., Cho C.H., Liu S. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol. Pharmacol. 2010, 79:608-617.
23. Liu B., Shi Z.L., Feng J., Tao H.M. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol. Int. 2008, 32:494-501.
24. Kardosh A., Soriano N., Pyrko P., Liu Y.T., Jabbour M., Hofman F.M., Schonthal A.H. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. J. Biomed. Sci. 2007, 14:647-662.
25. Sinicrope F.A., Half E., Morris J.S., Lynch P.M., Morrow J.D., Levin B., Hawk E.T., Cohen D.S., Ayers G.D., Stephens L.C. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol. Biomarkers Prev. 2004, 13:920-927.
26. Han C., Leng J., Demetris A.J., Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004, 64:1369-1376.
27. Cui W., Yu C.H., Hu K.Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 2005, 11:8213-8221.
28. Vogt T., McClelland M., Jung B., Popova S., Bogenrieder T., Becker B., Rumpler G., Landthaler M., Stolz W. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res. 2001, 11:587-599.
29. Zhang S., Suvannasankha A., Crean C.D., White V.L., Johnson A., Chen C.S., Farag S.S. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin. Cancer Res. 2007, 13:4750-4758.
30. Grivennikov S., Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
31. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15:79-80.
32. Klenke F.M., Abdollahi A., Bischof M., Gebhard M.M., Ewerbeck V., Huber P.E., Sckell A. Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo, Strahlenther. Onkol. 2010, 187:45-51.
33. Ma H.I., Chiou S.H., Hueng D.Y., Tai L.K., Huang P.I., Kao C.L., Chen Y.W., Sytwu H.K. Celecoxib and radioresistant glioblastoma-derived CD133(+) cells: improvement in radiotherapeutic effects. J. Neurosurg. 2010, 114:651-662.
34. Chen K.H., Hsu C.C., Song W.S., Huang C.S., Tsai C.C., Kuo C.D., Hsu H.S., Tsai T.H., Tsai C.Y., Woung L.C., Chiou S.H., Lu K.H., Chen Y.W. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Childs Nerv. Syst. 2010, 26:1605-1612.
35. Ahn Q., Jeong S.J., Lee H.J., Kwon H.Y., Han I., Kim H.S., Lee E.O., Ahn K.S., Jung M.H., Zhu S., Chen C.Y., Kim S.H. Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett. 2010, 298:212-221.
36. Gradilone A., Pulcinelli F.M., Lotti L.V., Trifiro E., Martino S., Gandini O., Gianni W., Frati L., Agliano A.M., Gazzaniga P. Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr. Cancer Drug Targets 2008, 8:414-420.
37. Yang Z., Xiao H., Jin H., Koo P.T., Tsang D.J., Yang C.S. Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int. J. Cancer 2010, 126:852-863.